GSK (NYSE:GSK) has received FDA approval for Jesduvroq, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), as a daily treatment for anemia associated with chronic kidney disease in adult dialysis patients. Jesduvroq is the first new medicine for anemia treatment in over 30 years, GSK noted. The drug is the only HIF-PHI to win FDA…